Aktienanalyse zu Nexalin Technology Inc (NXL)NXLNexalin Technology Inc

Nexalin Technology, Inc. is a medical device company. It engaged in design and development of neurostimulation products for mental health epidemics. It has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. It also operates PONM, which is a digital health platform. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Nexalin Technology Inc is not a good buy right now due to its extremely low RSI of 9.11, indicating it is oversold, and a significant year-to-date decline of 57.09%. The stock's recent performance has been poor, with a 5-day change of -24.72% and a 1-year change of -73.44%. The main risk is the company's ongoing losses, with a net income of -2,239,170 USD in Q2 2026, which raises concerns about its financial stability.